Zevra Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Net Income	-46.05	-26.77	-62.9	-12.76	-24.52	-56.47	-43.39	-16.52	-54.66	-24.46	Upgrade
Depreciation & Amortization	1.01	0.94	0.26	0.27	0.3	0.32	0.34	0.18	0.08	0.08	Upgrade
Share-Based Compensation	5.95	4.29	2.44	2.49	4.41	6.5	4.56	6.6	2.37	0.21	Upgrade
Other Operating Activities	5.55	2.82	16.3	8.06	-3.93	-4.56	5.39	-20.03	31.94	9.5	Upgrade
Operating Cash Flow	-33.54	-18.72	10.44	-1.94	-23.74	-54.2	-33.1	-29.77	-20.27	-14.67	Upgrade
Capital Expenditures	-0.3	-0.09	-0.1	-0.03	-0.03	-0.02	-0.18	-0.64	-0.14	-0.05	Upgrade
Acquisitions	-30.4	-14.09	0	0	0	0	0	0	0	0	Upgrade
Change in Investments	13.31	-22.54	-15.42	0	3.26	33.35	27.59	-45.2	-19	0	Upgrade
Investing Cash Flow	-17.39	-36.72	-15.52	-0.03	3.23	33.33	27.41	-45.85	-19.14	-0.05	Upgrade
Share Issuance / Repurchase	2.88	-4.4	155.43	0	0	28.4	0	0.14	60.31	0	Upgrade
Debt Issued / Paid	25.59	12.75	-40.98	2.82	4.94	-0.19	-0.16	62.17	-0.03	24.93	Upgrade
Other Financing Activities	-	-	-1.34	-0.08	-	-0.18	-0.05	-1.15	1.2	-1.93	Upgrade
Financing Cash Flow	28.46	8.35	113.11	2.74	4.94	28.02	-0.2	61.16	61.47	23	Upgrade
Exchange Rate Effect	0.04	0.2	0	0	0	0	0	0	0	0	Upgrade
Net Cash Flow	-22.42	-46.88	108.02	0.77	-15.56	7.15	-5.89	-14.46	22.06	8.29	Upgrade
Free Cash Flow	-33.83	-18.81	10.34	-1.97	-23.76	-54.22	-33.28	-30.42	-20.4	-14.72	Upgrade
Free Cash Flow Margin	-123.20%	-185.12%	36.08%	-14.84%	-185.08%	-	-	-	-	-	Upgrade
Free Cash Flow Per Share	-0.95	-0.55	0.35	-0.49	-12.82	-48.39	-36.34	-33.34	-44.30	-98.90	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).